HIPEC in ovarian cancer: new evidence supports its use
![](https://panoncology.com/wp-content/uploads/2023/10/HIPEC-in-ovarian-cancer-new-evidence-supports-its-use_QTI-1024x624.png)
The decision whether or not to add HIPEC to surgery in ovarian cancer recurrence is clear: intraoperative chemotherapy increases survival without added toxicity.
The decision whether or not to add HIPEC to surgery in ovarian cancer recurrence is clear: intraoperative chemotherapy increases survival without added toxicity.